Trial Profile
Investigation of the efficacy/safety and clinical dose of TAK-390MR for Erosive Esophagitis - A Phase II/III, Stratified-Randomized, Double-Blind, Parallel-Group, Multicenter Study on Efficacy and Safety of TAK-390MR by Comparison with AG-1749 in Patients with Erosive Esophagitis -
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 03 Jun 2016
Price :
$35
*
At a glance
- Drugs Dexlansoprazole (Primary) ; Lansoprazole
- Indications Erosive oesophagitis
- Focus Therapeutic Use
- Sponsors Takeda
- 03 Jun 2016 New trial record